Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.70 |
| ▸ | DRD4 | P21917 | 7/20 | 0.61 |
| ▸ | DRD2 | P14416 | 4/20 | 0.61 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.57 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11395220 | 0.79 | MCHR1 (0.77) | MCHR1DRD4DRD2 | |
| SCHEMBL7694198 | 0.78 | DRD2 (0.85) | MCHR1DRD4DRD2HTR2A | |
| SCHEMBL7694199 | 0.78 | DRD2 (0.85) | MCHR1DRD4DRD2HTR2A | |
| SCHEMBL678856 | 0.77 | MCHR1 (1.00) | MCHR1DRD4 | |
| SCHEMBL678857 | 0.77 | MCHR1 (1.00) | MCHR1DRD4 | |
| SCHEMBL1753725 | 0.77 | DRD4 (0.77) | MCHR1DRD4DRD2 | |
| SCHEMBL9872559 | 0.77 | DRD4 (0.78) | MCHR1DRD4 | |
| SCHEMBL12426323 | 0.76 | DRD4 (0.70) | MCHR1DRD4DRD2HTR2A | |
| SCHEMBL12426664 | 0.76 | DRD4 (0.70) | MCHR1DRD4DRD2HTR2A | |
| SCHEMBL14290681 | 0.76 | MCHR1 (0.67) | MCHR1DRD4DRD2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054312-A1 | SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054312-A1 | SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases | CDKN1A, CDK4, CDK2 | MCHR1 3752/4885DRD4 4357/4885DRD2 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.